Bioniz Therapeutics
20 articles about Bioniz Therapeutics
-
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
2/16/2022
Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform.
-
Bioniz Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference
11/9/2021
Bioniz Therapeutics, Inc., today announced that management will participate in a fireside chat at the upcoming Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1, 2021, at 1:00pm Eastern Time.
-
Bioniz Therapeutics Expands Board of Directors and Leadership Team as Company Advances Lead Drug Candidate in Late-Stage Clinical Trials
5/12/2021
Bioniz Therapeutics, Inc., ("Bioniz"), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases, announced today the appointment of Eric Carter, M.D., Ph.D., to the Board of Directors (BOD), and the hiring of Simon Daggett as Vice President, Clinical Operations and Project Management.
-
Bioniz Therapeutics Receives Orphan Drug Designation from the European Commission for BNZ-1 for Treatment of Cutaneous T-Cell Lymphoma
4/6/2021
Bioniz Therapeutics, Inc., ("Bioniz"), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases, today announced the European Commission (EC) has granted orphan designation to BNZ-1 for the treatment of cutaneous T-cell lymphoma (CTCL), a rare skin cancer.
-
Bioniz Therapeutics Appoints Dr. Alexandre Kaoukhov to Leadership Team
3/24/2021
Bioniz Therapeutics, Inc., ("Bioniz"), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases, announced today the appointment of Alexandre Kaoukhov, M.D., as Senior Vice President and Head of Clinical Development
-
Data from a Phase I/II clinical trial was presented Saturday during the 62nd ASH Annual Meeting and Exposition (ASH).
-
Bioniz Announces Positive Clinical Data of BNZ-1, First Anti-Cytokine Therapy to Demonstrate Efficacy in Treating Refractory Cutaneous T-Cell Lymphoma
12/5/2020
BNZ-1 showed an overall response rate (ORR) of 63.2% based on the Global Response Score (GRS) in a heavily pretreated, relapsed and refractory CTCL patient population
-
Bioniz Announces Oral Presentation at ASH 2020 of Positive Clinical Data of BNZ-1 for the Treatment of Refractory Cutaneous T-Cell Lymphoma
11/5/2020
As a multi-cytokine inhibitor, BNZ-1 is a novel immuno-oncology drug that integrates inhibition of malignant cells, activation of tumor immunity, and suppression of inflammation
-
Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma
7/20/2020
Bioniz Therapeutics, Inc. announced encouraging interim clinical data from its Phase 1/2 open-label clinical study of its lead product candidate BNZ-1 in patients with refractory Cutaneous T-Cell Lymphoma.
-
Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology
1/9/2020
Almirall, S.A. (ALM) has announced today the execution of an option agreement to acquire Bioniz Therapeutics, Inc. a clinical stage biopharmaceutical company based in Irvine, California, which develops first-in-class peptide treatments that selectively inhibit multiple cytokines to treat immuno-inflammatory diseases and T-cell malignancies
-
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
1/9/2020
Bioniz Therapeutics, Inc. announced the execution of an option agreement for acquisition by Almirall including its lead candidate, BNZ-1.
-
Bioniz Therapeutics Announces Positive Phase 1b Clinical Study Results for Investigational Agent BNZ-1
5/1/2018
Bioniz Therapeutics, Inc. announced top-line results from its multiple ascending dose Phase 1b clinical trial of BNZ-1.
-
Bioniz Therapeutics Initiates Phase 1/2 Clinical Study of BNZ‑1 in T-Cell Leukemia and Lymphoma
4/4/2018
Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company developing first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and T-cell malignancies, today announced that it has initiated a Phase 1/2 open-label clinical study of its lead product candidate BNZ-1
-
Forbes recently interviewed Nazli Azimi, the CEO and co-founder of Bioniz Therapeutics.
-
Bioniz Therapeutics Appoints Graham Cooper to its Board of Directors
12/6/2017
Most recently, Mr. Cooper was the CFO of Receptos from 2013 until its sale in 2015 to Celgene for $7.8B.
-
Bioniz Presents Data Demonstrating The Synergistic Effects Of Cytokines IL-15 And IL-21 In Celiac Disease Pathogenesis
9/13/2017
-
Bioniz Reports Top-Line Phase I Clinical Study Results For BNZ-1, A Novel Multi-Cytokine Inhibitor
7/19/2017
-
Bioniz Appoints Paul Frohna M.D., Ph.D., Pharm. D., As Senior Vice President Of Clinical Development
12/21/2016
-
Backed by Takeda, SoCal Startup Bioniz Bags $13 Million and Taps Former Allergan CEO as Chairman of the Board
8/1/2016
-
Bioniz Appoints Fredrik Wiklund As Chief Operating Officer
5/3/2016